Implantable Polymer Depots for Localized Sustained Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy delivery systems face challenges in targeting cancer cells effectively while minimizing harm to healthy tissues, due to rapid clearance by the reticuloendothelial system and premature drug release, leading to inefficient drug localization and systemic side effects.
Innovation Solution
Development of implantable polymer depots that release chemotherapeutic agents locally and sustainably, configured with a therapeutic region and a control region containing a releasing agent to form diffusion openings, allowing controlled release of drugs directly at the tumor site for extended periods, reducing systemic circulation and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic chemotherapy delivery is used to treat cancer, then the drug can reach target cells through passive diffusion and active targeting, but the majority of the drug does not reach the target and acts on other tissues causing systemic side effects
Solution Approach 1:
The patent extracts the chemotherapy drug from systemic circulation and delivers it directly to the tumor site through implantable depots. This removes the drug from the harmful systemic environment and concentrates it where needed, eliminating the majority of systemic side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent introduces polymer-based implantable depots as intermediary delivery vehicles. These depots serve as localized reservoirs that control drug release directly at the tumor site, acting as a mediator between the drug and target cells to prevent systemic distribution and reduce harmful effects on non-target tissues.
2Duration of action of moving object
If liposomes are used to encapsulate toxins for targeted delivery, then the drug residence time is enhanced and protection from degradation is provided, but rapid clearance by phagocytic cells and lack of specific tumor targeting limits clinical utility
Solution Approach 1:
The patent changes the physical and chemical parameters of the delivery system by using polymer-based materials with controlled degradation rates and porosity. This allows for sustained drug release over extended periods while enabling specific tumor targeting through localized implantation, overcoming the limitations of liposomal systems.
Solution Approach 2:
The patent employs composite polymer materials that combine biocompatibility, controlled degradation properties, and drug loading capabilities. These composite materials provide both prolonged drug residence time and reliable tumor targeting, addressing the shortcomings of single-material liposomal systems.
3Quantity of substance
If polymer-based drug delivery systems are used to achieve high therapeutic concentrations at the tumor site, then localization is improved, but the complexity of the delivery system increases
Solution Approach 1:
The patent divides the delivery system into simple, modular implantable depots that can be directly placed at the tumor site. This segmentation into discrete, manageable units simplifies the overall system complexity while maintaining the ability to achieve high therapeutic concentrations through localized delivery.
4Reliability
If controlled release depot systems are implanted intratumorally or adjacent to cancerous tissue, then localized chemotherapy efficacy is enhanced and patient morbidity is reduced, but the need for precise implantation and controlled release mechanisms increases system complexity
Solution Approach 1:
The patent designs polymer depots with self-regulating release mechanisms that control drug release based on local environmental conditions such as pH, enzyme presence, or hydration. This self-service capability reduces the need for complex external control systems while maintaining reliable localized treatment efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymer depots ensure prolonged and controlled release of chemotherapeutic agents directly at the tumor site, enhancing treatment efficacy while minimizing systemic toxicity and side effects, thereby improving cancer treatment outcomes.
Implementation Method 1
a control region comprising a polymer and a releasing agent mixed with the polymer, wherein the releasing agent is configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region
Data Source
AI summary
The present technology relates to implantable depots for the local, sustained, controlled release of a therapeutic agent to treat cancer. An implantable depot may comprise a biodegradable polymer mixed with a locally-acting therapeutic agent configured to treat cancer. The depot may be configured to be implanted within a patient proximate cancerous tissue and, while implanted, provide sustained exposure of the therapeutic agent at the treatment site for a period of time that is no less than 5 days.